Ts- AML and non–ts-AML population disease characteristics and outcomes
| Variable . | ts-AML (N = 254) . | Non–ts-AML (N = 2659) . | P . |
|---|---|---|---|
| Median (range) or no./proportion (%) . | |||
| Age, y | 68 (15-92) | 63 (12-92) | <.01 |
| WBCs, ×109/L | 4 (0-195) | 5 (0.1-479) | .13 |
| Platelets, ×109/L | 30 (1-936) | 46 (1-1 069) | .03 |
| PB blasts, % | 15 (3-98) | 15 (0-99) | .13 |
| LDH, IU/L | 747 (13-22 798) | 762 (190-42 000) | .12 |
| BM blasts, % | 32 (6-94) | 46 (0-99) | <.01 |
| t-AML, no. (%) | 54 (21) | 454 (17) | .27 |
| Prior AHD treatment, no. (%) | |||
| Hypomethylating agents | 185 (73) | — | — |
| Lenalidomide/thalidomide | 16 (6) | — | — |
| Others | 53 (21) | — | — |
| Karyotype, no. (%) | |||
| Adverse | 109 (43) | 849 (32) | .005 |
| Diploid/intermediate | 118 (46) | 1 159 (44) | .86 |
| Favorable | 3 (1) | 226 (8.5) | <.001 |
| Not done/insufficient | 24 (10) | 558 (15.5) | |
| Mutations* | |||
| FLT3-ITD | 24/220 (11) | 349/2 200 (16) | .052 |
| FLT3D835 | 9/220 (4) | 120/2 200 (5.4) | .39 |
| NPM1 | 17/157 (11) | 293/1 462 (20) | .005 |
| RAS | 42/214 (20) | 278/1 980 (14) | .03 |
| RUNX1 | 11/35 (31) | 30/350 (8.5) | <.001 |
| ASXL1 | 13/34 (38) | 33/354 (9) | <.001 |
| TET2 | 18/55 (33) | 44/359 (12) | <.001 |
| DNMT3A | 14/75 (19) | 110/835 (13) | .18 |
| IDH1 | 13/115 (11) | 113/1 100 (10) | .72 |
| IDH2 | 18/115 (16) | 141/1 100 (13) | .39 |
| TP53 | 9/64 (14) | 112/613 (18) | .40 |
| Variable . | ts-AML (N = 254) . | Non–ts-AML (N = 2659) . | P . |
|---|---|---|---|
| Median (range) or no./proportion (%) . | |||
| Age, y | 68 (15-92) | 63 (12-92) | <.01 |
| WBCs, ×109/L | 4 (0-195) | 5 (0.1-479) | .13 |
| Platelets, ×109/L | 30 (1-936) | 46 (1-1 069) | .03 |
| PB blasts, % | 15 (3-98) | 15 (0-99) | .13 |
| LDH, IU/L | 747 (13-22 798) | 762 (190-42 000) | .12 |
| BM blasts, % | 32 (6-94) | 46 (0-99) | <.01 |
| t-AML, no. (%) | 54 (21) | 454 (17) | .27 |
| Prior AHD treatment, no. (%) | |||
| Hypomethylating agents | 185 (73) | — | — |
| Lenalidomide/thalidomide | 16 (6) | — | — |
| Others | 53 (21) | — | — |
| Karyotype, no. (%) | |||
| Adverse | 109 (43) | 849 (32) | .005 |
| Diploid/intermediate | 118 (46) | 1 159 (44) | .86 |
| Favorable | 3 (1) | 226 (8.5) | <.001 |
| Not done/insufficient | 24 (10) | 558 (15.5) | |
| Mutations* | |||
| FLT3-ITD | 24/220 (11) | 349/2 200 (16) | .052 |
| FLT3D835 | 9/220 (4) | 120/2 200 (5.4) | .39 |
| NPM1 | 17/157 (11) | 293/1 462 (20) | .005 |
| RAS | 42/214 (20) | 278/1 980 (14) | .03 |
| RUNX1 | 11/35 (31) | 30/350 (8.5) | <.001 |
| ASXL1 | 13/34 (38) | 33/354 (9) | <.001 |
| TET2 | 18/55 (33) | 44/359 (12) | <.001 |
| DNMT3A | 14/75 (19) | 110/835 (13) | .18 |
| IDH1 | 13/115 (11) | 113/1 100 (10) | .72 |
| IDH2 | 18/115 (16) | 141/1 100 (13) | .39 |
| TP53 | 9/64 (14) | 112/613 (18) | .40 |
—, Not applicable; BM, bone marrow; LDH, lactate dehydrogenase; PB, peripheral blood.
Molecular mutational data available in limited samples as numerated in the denominators.